Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bron – page 3

478 clinical trials in Bron, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bron at a glance
478
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

478 trials in Bron

Open in trial search

Ornithine transcarbamoylase deficiency

Recruiting

Long‑Term Safety Follow‑up of Ornithine Transcarbamylase Deficiency Patients Treated with ECUR‑506D and ECUR‑506A

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Adeno-Associated Virus Serotype Rh79 Containing The Human Otc Gene
  • Sponsor:Iecure Inc.

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Small cell lung cancer extensive stage

Recruiting

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Depression+1

Recruiting

Efficacy of high- and low-dose psilocybin in preventing relapse in adults with severe alcohol use disorder and depressive symptoms after detoxification

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Psilocybine
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Factor VIII deficiency

Recruiting

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Factor VIII deficiency

Recruiting

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Epilepsy

Recruiting

[18F]CPFPX PET in Patients With Drug-Resistant Epilepsy and Healthy Subjects

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · Healthy volunteers
  • Substances:[18F]CPFPX
  • Sponsor:Hospices Civils De Lyon

Parkinson's disease

Recruiting

A study using [11C]ORM-13070 to examine the effects of aging and Parkinson's disease on specific brain receptors.

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE
  • Sponsor:Hospices Civils De Lyon

Progressive supranuclear palsy

Recruiting

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Novartis Pharma AG

Factor VIII deficiency+1

Recruiting

A study on the long-term safety and effectiveness of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Fidanacogene Elaparvovec
  • Sponsor:Pfizer Inc.

Rett syndrome

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bron

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on multiple sclerosis and Parkinson's disease, including advanced PET imaging studies and evaluation of novel therapeutic approaches.

  • Multiple Sclerosis Imaging
  • Parkinson's Disease Treatment
  • Essential Tremor Studies

Studies include neuroinflammation assessment and serotonergic receptor expression analysis.

02 Brain Tumors

Comprehensive research into glioblastoma treatment approaches, combining innovative therapies with standard protocols.

  • Newly Diagnosed Glioblastoma
  • Nanoparticle Therapy
  • Combined Treatment Approaches

Integration of radiotherapy, chemotherapy, and novel therapeutic agents for improved patient outcomes.

03 Rare Diseases

Targeted research on rare conditions including Dravet Syndrome and Alagille syndrome, focusing on innovative therapeutic approaches.

  • Hereditary Conditions
  • Genetic Disorders
  • Novel Treatment Evaluation

Emphasis on developing effective treatments for previously undertreated rare conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.